What are the USPSTF guidelines on pharmacologic interventions for breast cancer risk reduction?

Updated: Feb 04, 2021
  • Author: Pavani Chalasani, MD, MPH; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print

The USPSTF updated its guidelines for primary breast cancer risk reduction in 2019. [178]  The USPSTF recommends that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors.

The USPSTF recommendation applies to asymptomatic women 35 years and older, including women with previous benign breast lesions on biopsy (eg, atypical ductal or lobular hyperplasia and lobular carcinoma in situ). The recommendation does not apply to women with a current or previous diagnosis of breast cancer or ductal carcinoma in situ.. [178]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!